Literature DB >> 9037609

NASBA technology: isothermal RNA amplification in qualitative and quantitative diagnostics.

J W Romano1, K G Williams, R N Shurtliff, C Ginocchio, M Kaplan.   

Abstract

Nucleic acid amplification technologies allow for the development of highly sensitive and specific diagnostic assays. The capacity to amplify and detect analyte targets, which may be present in a clinical sample as a single copy; is characteristic of many of these amplification technologies. NASBA is an isothermal method of nucleic acid amplification with such capability, and is particularly well suited for the amplification of RNA analytes. NASBA utilizes the coordinated activities of three enzymes (AMV-RT, RNase H, T7 RNA polymerase), and two oligonucleotide primers which are specific for the analyte target. The amplification process is part of a total system which includes a versatile nucleic acid isolation procedure, and powerful detection methodology. In this report, the development of NASBA technology for the detection of human Retrovirus RNA will be discussed. Specifically, a qualitative NASBA assay for the RNA of HTLV I, and a quantitative NASBA assay for HIV-1 will be described.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9037609     DOI: 10.3109/08820139709048912

Source DB:  PubMed          Journal:  Immunol Invest        ISSN: 0882-0139            Impact factor:   3.657


  38 in total

Review 1.  Characteristics and applications of nucleic acid sequence-based amplification (NASBA).

Authors:  Birgit Deiman; Pierre van Aarle; Peter Sillekens
Journal:  Mol Biotechnol       Date:  2002-02       Impact factor: 2.695

2.  Antibody to the gp120 V1/V2 loops and CD4+ and CD8+ T cell responses in protection from SIVmac251 vaginal acquisition and persistent viremia.

Authors:  Shari N Gordon; Melvin N Doster; Rhonda C Kines; Brandon F Keele; Egidio Brocca-Cofano; Yongjun Guan; Poonam Pegu; Namal P M Liyanage; Monica Vaccari; Nicolas Cuburu; Christopher B Buck; Guido Ferrari; David Montefiori; Michael Piatak; Jeffrey D Lifson; Anastasia M Xenophontos; David Venzon; Marjorie Robert-Guroff; Barney S Graham; Douglas R Lowy; John T Schiller; Genoveffa Franchini
Journal:  J Immunol       Date:  2014-11-14       Impact factor: 5.422

3.  An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge.

Authors:  S L Buge; E Richardson; S Alipanah; P Markham; S Cheng; N Kalyan; C J Miller; M Lubeck; S Udem; J Eldridge; M Robert-Guroff
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Regulatory T-cell markers, indoleamine 2,3-dioxygenase, and virus levels in spleen and gut during progressive simian immunodeficiency virus infection.

Authors:  Adriano Boasso; Monica Vaccari; Anna Hryniewicz; Dietmar Fuchs; Janos Nacsa; Valentina Cecchinato; Jan Andersson; Genoveffa Franchini; Gene M Shearer; Claire Chougnet
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

5.  Antibodies to gp120 and PD-1 expression on virus-specific CD8+ T cells in protection from simian AIDS.

Authors:  Monica Vaccari; Rabih Halwani; L Jean Patterson; Adriano Boasso; Jennifer Beal; Elzbieta Tryniszewska; Anna Hryniewicz; David Venzon; Elias K Haddad; Mohamed El-Far; Margherita Rosati; George N Pavlakis; Barbara K Felber; Saleh Al-Muhsen; Marjorie Robert-Guroff; Rafick-Pierre Sekaly; Genoveffa Franchini
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

6.  Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure.

Authors:  Monica Vaccari; Brandon F Keele; Steven E Bosinger; Melvin N Doster; Zhong-Min Ma; Justin Pollara; Anna Hryniewicz; Guido Ferrari; Yongjun Guan; Donald N Forthal; David Venzon; Claudio Fenizia; Tia Morgan; David Montefiori; Jeffrey D Lifson; Chris J Miller; Guido Silvestri; Margherita Rosati; Barbara K Felber; George N Pavlakis; James Tartaglia; Genoveffa Franchini
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

7.  CD4+ T-cell loss and delayed expression of modulators of immune responses at mucosal sites of vaccinated macaques following SIV(mac251) infection.

Authors:  M Vaccari; A Boasso; Z-M Ma; V Cecchinato; D Venzon; M N Doster; W P Tsai; G M Shearer; D Fuchs; B K Felber; G N Pavlakis; C J Miller; G Franchini
Journal:  Mucosal Immunol       Date:  2008-09-17       Impact factor: 7.313

8.  Glucocorticoid treatment at moderate doses of SIVmac251-infected rhesus macaques decreases the frequency of circulating CD14+CD16++ monocytes but does not alter the tissue virus reservoir.

Authors:  Marcin Moniuszko; Namal P M Liyanage; Melvin N Doster; Robyn Washington Parks; Kamil Grubczak; Danuta Lipinska; Katherine McKinnon; Charles Brown; Vanessa Hirsch; Monica Vaccari; Shari Gordon; Poonam Pegu; Claudio Fenizia; Robert Flisiak; Anna Grzeszczuk; Milena Dabrowska; Marjorie Robert-Guroff; Guido Silvestri; Mario Stevenson; Joseph McCune; Genoveffa Franchini
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01       Impact factor: 2.205

9.  Combined effect of antiretroviral therapy and blockade of IDO in SIV-infected rhesus macaques.

Authors:  Adriano Boasso; Monica Vaccari; Dietmar Fuchs; Andrew W Hardy; Wen-Po Tsai; Elzbieta Tryniszewska; Gene M Shearer; Genoveffa Franchini
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

10.  Reduced protection from simian immunodeficiency virus SIVmac251 infection afforded by memory CD8+ T cells induced by vaccination during CD4+ T-cell deficiency.

Authors:  Monica Vaccari; Joseph Mattapallil; Kaimei Song; Wen-Po Tsai; Anna Hryniewicz; David Venzon; Maurizio Zanetti; Keith A Reimann; Mario Roederer; Genoveffa Franchini
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.